SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma

Suzanne Lentzsch, Gary Elliott, G. David Roodman

Research output: Contribution to journalReview article

12 Scopus citations

Abstract

Non-steroidal anti-inflammatory drugs have been shown to inhibit carcinogenesis in colon cancer, and to induce apoptosis in a variety of tumor cell lines. Some anti-tumor effects are thought to be related to their cyclooxygenase-2-inhibitory activity, but recent studies have shown that non-steroidal anti-inflammatory drugs exert their anti-tumor effect via cyclooxygenase-2-independent mechanism. SDX-308 (CEP-18082) is a non-cyclooxygenase-2-inhibiting indole-pyran analog and is structurally related to SDX-101, an R-enantiomer of etodolac. SDX-308 has a potent anti-myeloma effect and shows synergism in combination with other drugs for the treatment of chronic lymphocytic leukemia. In addition SDX-308 inhibits osteoclast formation and activity and thereby might be an attractive drug for the treatment of diseases with increased osteoclast activity such as osteolytic lesions in multiple myeloma and metastatic carcinomas, as well as osteoporosis. This review covers future application of SDX-308 as an anti-myeloma drug regulating increased osteoclast activity.

Original languageEnglish (US)
Pages (from-to)511-516
Number of pages6
JournalArchiv der Pharmazie
Volume340
Issue number10
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Keywords

  • Anticancer activity
  • CEP-18082
  • Multiple myeloma
  • SDX-308

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma'. Together they form a unique fingerprint.

  • Cite this